Select Language
Claudin18.2 Proteins
Claudin is a family of proteins first discovered by Furuse in 1998 , which contains at least 27 members. It's a type of four-pass transmembrane protein that expressed at the tight junction of epithelium and endothelium which is a component of tight junction strands that play critical roles in maintaining cell polarity and signal transductions. Claudin 18.2, a subtype of Claudin 18, is characterized by limited expression in normal differentiated gastric mucosal epithelial cells but aberrantly high expression in various malignant tumors, including gastric cancer, pancreatic cancer, cholangiocarcinoma, ovarian cancer, and lung cancer, making it an attractive target for immunotherapy. Thus it has emerged as an ideal target for immunotherapy including monoclonal antibody, bispecific antibody, ADC and CAR-T therapy.
Restricted by the surface area of the cell membrane and the potential cytotoxicity of overexpressed membrane proteins, the expression level of recombinant four-pass Claudin 18.2 proteins is much lower than that of soluble proteins. Furthermore, it is necessary to screen suitable detergents or lipids to maintain spatial conformation and protein activity in the process of extraction and purification. So that makes it very difficult to obtain Claudin 18.2 antigen with high purity, native conformation and activity, which seriously hinders the development of drugs and therapies targeting Claudin 18.2.
To solve the challenge of obtaining complete conformation of four-pass transmembrane protein Claudin 18.2,ACROBiosystems has successfully developed full-length Claudin 18.2-VLP, complete epitope Claudin 18.2-Detergent, and detergent-free Claudin 18.2-Nanodisc proteins by relying on the technology platforms of multi-pass transmembrane proteins. These products have been validated through ELISA/BLI/SPR to exhibit high biological activity, making them suitable for use in drug discovery and development. Meanwhile, we offer Claudin 18.2 Stable Cell Line and integrated SPR & BLI analytical service to meet the needs of drug development, assist drug clinical declaration.
OrderProduct feature
The following ELISA/SPR/BLI protocols are available for free.
Claudin 18.2-VLP
Advantages
Full-length Claudin 18.2
Enhanced humoral and cellular immune responses
Optimal target presentation to APC and phage display because of its 100-300nm in size
Suitable for immunization/ELISA/SPR/BLI/cell-based assay /CAR detection
Enhanced humoral and cellular immune responses
Optimal target presentation to APC and phage display because of its 100-300nm in size
Suitable for immunization/ELISA/SPR/BLI/cell-based assay /CAR detection
Claudin 18.2-VLP
Correct assembly validated by SEM
Full-length Claudin 18.2-VLP (Cat. No.CL2-H52P7) has been observed under an electron microscope to ensure that it is assembled correctly.
High bioactivity validated by ELISA
Immobilized Human Claudin-18.2 Full Length Protein-VLP (Cat. No. CL2-H52P7) at 5 μg/mL (100 μL/well) can bind Monoclonal Anti-Chimeric Claudin-18.2 Antibody, Human IgG1 with a linear range of 0.2-3 ng/mL (QC tested).
High affinity validated by SPR
Human Claudin-18.2 Full Length Protein-VLP (Cat. No. CL2-H52P7) captured on CM5 Chip via Anti-Claudin-18.2 antibody can bind Anti-Claudin-18.2 antibody with an affinity constant of 0.374 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Suitable for CAR detection
2e5 of Anti-Claudin-18.2 CAR-293 cells were stained with 100 μL of 3 μg/mL of Fluorescent Human Claudin-18.2 Full Length Protein-VLP (Cat. No.CL2-HF218) and negative control protein respectively, FITC signals was used to evaluate the binding activity (Routinely tested).
Claudin 18.2-Detergent
High bioactivity validated by ELISA
Immobilized Human Claudin-18.2, His,Twin-Strep Tag (Cat. No. CL2-H5587) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Chimeric Claudin-18.2 Antibody, Human IgG1 with a linear range of 0.1-2 ng/mL (QC tested).
High affinity validated by SPR
Anti-Claudin-18.2 mAb captured on CM5 chip via anti-Human IgG (Fc) antibody can bind Human Claudin-18.2, His,Twin-Strep Tag (Cat. No. CL2-H5587) with an affinity constant of 6.72 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore T200) (Routinely tested).
Claudin 18.2-Nanodisc
High bioactivity validated by ELISA
Immobilized Biotinylated Human Claudin-18.2 Protein, His,Avitag&Flag Tag (Cat. No. CL2-H85D4) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Monoclonal Anti-Chimeric Claudin-18.2 Antibody, Human IgG1 with a linear range of 0.1-2 ng/mL (QC tested).
High affinity validated by SPR
Monoclonal Anti-Chimeric Claudin-18.2 Antibody, Human IgG1 captured on Protein A Chip can bind Human / Cynomolgus Claudin-18.2, His,Twin-Strep Tag (Cat. No. CL2-H5586) with an affinity constant of 12.6 nM as determined in SPR assay (Biacore 8K) (Routinely tested).
Clinical drug information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| 89Zr-NY005 | 89Zr-NY005 | Clinical | Wuxi Nuoyu Pharmaceutical Technology Co Ltd | Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| CTB-001(Nanjing Bioheng) | CTB-001; CTB001 | Clinical | Nanjing Bioheng Biotech Co Ltd | Pancreatic Neoplasms; Stomach Neoplasms | Details |
| 124I-18B10 | 124I-18B10; 124-I-18-B-10 | Clinical | Beijing Cancer Hospital, Transcenta Holding Ltd | Gastrointestinal Neoplasms | Details |
| CLDN18.2 UCAR-T cell therapy | CLDN18.2 UCAR-T | Clinical | T-Maximum Pharmaceutical (Suzhou) Co Ltd | Stomach Neoplasms | Details |
| XKDCT-086 | XKDCT086; XKDCT-086 | Clinical | The Affiliated Hospital Of Qingdao University | Stomach Neoplasms | Details |
| LCAR-C18S CAR-T cell therapy (Legend) | LB-1908; LCAR-C18S; LCAR-C-18-S | Phase 1 Clinical | Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details | |
| HBM-1029 | HBM-1029; HBM1029 | Phase 1 Clinical | Harbour Biomed | Esophageal Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| LM-102 | LM-102 | Phase 1 Clinical | LaNova Medicines Ltd | Biliary Tract Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| QL-1779 | QL-1779; QL1779 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Solid tumours | Details |
| IBI-360 | IBI-360 | Phase 1 Clinical | Neoplasms; Solid tumours | Details | |
| FL-301 | NBL-015; FL-301 | Phase 1 Clinical | Novarock Biotherapeutics Ltd | Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| IBI-389 | IBI-389 | Phase 1 Clinical | Esophageal Neoplasms; Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details | |
| CLDN 18.2 CAR-T cell therapy (Shanghai Longyao) | LY-011 | Phase 1 Clinical | Shanghai Longyao Biological Technology Co Ltd | Pancreatic Neoplasms; Stomach Neoplasms | Details |
| BA-1105 | BA1105; BA-1105 | Phase 1 Clinical | Shandong Boan Biotechnology Co Ltd | Esophageal Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| SG-1906 | SG-1906; SG1906 | Phase 1 Clinical | Hangzhou Shangjian Biotechnology Co Ltd | Neoplasms; Solid tumours | Details |
| DR-30303 | DR-30303 | Phase 1 Clinical | Zhejiang Doer Biologics Corp | Solid tumours | Details |
| BC-007 (Dragonboat Biopharmaceutical) | BC-007 | Phase 1 Clinical | Dragonboat Biopharmaceutical | Neoplasms; Solid tumours | Details |
| BC-008 | BC-008 | Phase 1 Clinical | Dragonboat Biopharmaceutical | Neoplasms; Solid tumours | Details |
| TORL-2-307-ADC | TORL-2-307-ADC | Phase 1 Clinical | Torl Biotherapeutics LLC | Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| TORL-2-307-MAB | TORL-2-307-MAB | Phase 1 Clinical | Torl Biotherapeutics LLC | Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| IBI-345 | IBI-345 | Phase 1 Clinical | Solid tumours | Details | |
| RD-07 | RD-07 | Phase 1 Clinical | Peking University | Solid tumours | Details |
| PM-3023 | PM-3023 | Phase 1 Clinical | Solid tumours | Details | |
| HEC-016 | HEC-016 | Phase 1 Clinical | People Hospital Of Luohu,Shenzhen | Esophageal Neoplasms; Pancreatic Neoplasms; Stomach Neoplasms | Details |
| ASP-2138 | ASP-2138 | Phase 1 Clinical | Astellas Pharma Global Development Inc, Xencor Inc | Carcinoma, Pancreatic Ductal; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Stomach Neoplasms | Details |
| CT-048 | CT-048; KJ-C1807; KJ-C-1807 | Phase 1 Clinical | Carsgen Biomedicine (Shanghai) Co Ltd | Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Stomach Neoplasms | Details |
| Ori-C-613 | Ori-C-613; OriC-613; Ori-C613 | Phase 1 Clinical | OriCell Therapeutics Co Ltd | Solid tumours | Details |
| LB-1904 | LB-1904 | Phase 1 Clinical | Stomach Neoplasms | Details | |
| RB-0011 | RB0011; RB-0011 | Phase 1 Clinical | Ruiyang (Suzhou) Biological Technology Co Ltd | Solid tumours | Details |
| BA-1301 | BA-1301; BA1301 | Phase 1 Clinical | Shandong Boan Biotechnology Co Ltd | Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| BIO-008 | BIO-008 | Phase 1 Clinical | Shijiazhuang Yiling Pharmaceutical Co Ltd | Solid tumours | Details |
| TQB-2103 | TQB2103; TQB-2103 | Phase 1 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Neoplasms | Details |
| AHT-101 | AHT-101; AHT101 | Phase 1 Clinical | Guangxi Lugang Biomedical Technology Co Ltd | Solid tumours | Details |
| AK-132 | AK132; AK-132 | Phase 1 Clinical | Neoplasms; Solid tumours | Details | |
| 68Ga-PMD22(Peking Union Medical College Hospital) | Phase 1 Clinical | Peking Union Medical College Hospital | Gastrointestinal Neoplasms | Details | |
| GC-506 | GC506; GC-506 | Phase 1 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd | Gastroesophageal Junction Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| AZD-6422 | AZD6422; AZD-6422 | Phase 1 Clinical | Astrazeneca Plc | Gastrointestinal Neoplasms | Details |
| AHT-102 | AHT102; AHT-102 | Phase 1 Clinical | Guangxi Lugang Biomedical Technology Co Ltd | Solid tumours | Details |
| BL-M05D1 | BL-M05D1; BLM05D1 | Phase 1 Clinical | Sichuan Baili Pharmaceutical Co Ltd, SystImmune | Biliary Tract Neoplasms; Carcinoma, Pancreatic Ductal; Esophageal adenocarcinoma; Solid tumours; Stomach Neoplasms | Details |
| LNF-2007 | LNF-2007; LNF2007 | Phase 1 Clinical | Shandong New Time Pharmaceutical Co Ltd | Solid tumours | Details |
| Cord Blood-Derived CAR-NK Cells therapy (Rongu Biotechnology) | CB CAR-NK182; RG-CLDN18.2 | Phase 1 Clinical | Hangzhou Rongu Biotechnology Co Ltd | Pancreatic Neoplasms; Stomach Neoplasms | Details |
| SPX-102 | SPX-102 | Phase 1 Clinical | Sparx Therapeutics Inc | Neoplasms | Details |
| HD-004 | HD004; HD-004 | Phase 1 Clinical | Huadao (Shanghai) Biopharma Co Ltd | Solid tumours | Details |
| [68Ga]Ga-NODAGA-SNA014 | 68Ga-SNA014; [68Ga]Ga-NODAGA-SNA014; SNA-014 | Phase 1 Clinical | Smartnuclide Biopharma | Adenocarcinoma; Pancreatic Neoplasms | Details |
| SIBP-A18 | SIBPA18; SIBP-A18 | Phase 1 Clinical | Shanghai Institute of Biological Products Co Ltd | Solid tumours | Details |
| CT-225 | XKDCT225; XKDCT-225; CT225 | Phase 1 Clinical | Shenzhen Celconta Life Science Co Ltd | Solid tumours | Details |
| Claudin18.2-targeted CAR-T Cells therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine) | Phase 1 Clinical | Second Affiliated Hospital School Of Zhejiang University School Of Medicine | Colorectal Neoplasms | Details | |
| Claudin18.2-targeted CAR-DCs therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine) | Phase 1 Clinical | Second Affiliated Hospital School Of Zhejiang University School Of Medicine | Colorectal Neoplasms | Details | |
| Gresonitamab | AMG-910 | Phase 1 Clinical | Amgen Inc | Adenocarcinoma; Esophageal Neoplasms; Stomach Neoplasms | Details |
| Claudin18.2 CAR-T cell therapy (Ucello Therapeutics) | Phase 1 Clinical | Ucello Therapeutics Co Ltd | Solid tumours | Details | |
| CBG-131 | CBG-131; CBG131 | Phase 1 Clinical | Carbiogene Therapeutics Co Ltd | Pancreatic Neoplasms; Stomach Neoplasms | Details |
| Claudin18.2 Targeted Activated Dendritic Cells therapy (Frontiergate Biopharm) | Phase 1 Clinical | Frontiergate Biopharm (Hainan) Co Ltd | Pancreatic Neoplasms | Details | |
| Claudin18.2 Targeted CAR-T Cells therapy (Frontiergate Biopharm) | Phase 1 Clinical | Frontiergate Biopharm (Hainan) Co Ltd | Pancreatic Neoplasms | Details | |
| KD-496 | KD-496(4th); KD-496 | Phase 1 Clinical | Nanjing Kaidi Medical Technology Co Ltd | Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Recombinant humanized anti-Claudin 18.2 monoclonal antibody (CARsgen) | AB-011 | Phase 1 Clinical | Carsgen Biomedicine (Shanghai) Co Ltd, Kaixing Life Technology (Shanghai) Co Ltd | Esophageal Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| RC-118 | RC-118; YH005 ADC | Phase 2 Clinical | Gastroesophageal Junction Neoplasms; Solid tumours; Stomach Neoplasms | Details | |
| Recombinant humanized monoclonal antibody MIL93(Mabworks) | MIL-93 | Phase 2 Clinical | Beijing Mabworks Biotech Co Ltd | Gastroesophageal Junction Neoplasms; Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Q-1802 | Q-1802 | Phase 2 Clinical | Qure Biotechnology (Shanghai) Co Ltd | Esophageal Neoplasms; Gastrointestinal Neoplasms; Solid tumours | Details |
| Givastomig | TJ-CD4B; ABL-111; TJ-CLDN4B; TJ-033721; TJ-CD4B/ABL111 | Phase 2 Clinical | I-Mab Biopharma Co Ltd | Biliary Tract Neoplasms; Carcinoma, Pancreatic Ductal; Esophageal adenocarcinoma; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Neoplasm Metastasis; Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| SOT-102 | SOT-102; SOT102; SO-N102 | Phase 2 Clinical | Sotio Biotech AG | Pancreatic Neoplasms; Stomach Neoplasms | Details |
| ATG-022 | ATG-022; ATN-022 | Phase 2 Clinical | Antengene Corporation Co Ltd | Gastroesophageal Junction Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| SKB-315 | SKB-315; SKB315; MK1200; MK-1200 | Phase 2 Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Esophageal Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Spevatamig | PT-886; PT886 | Phase 2 Clinical | Phanes Therapeutics Inc | Biliary Tract Neoplasms; Carcinoma, Pancreatic Ductal; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| PM-1032 | PM1032; PM-1032 | Phase 2 Clinical | Shanghai Genechem Co Ltd | Neoplasms; Pancreatic Neoplasms | Details |
| LCB-02A | LCB-02A | Phase 2 Clinical | Legochem Biosciences Inc | Hematologic Neoplasms; Solid tumours | Details |
| BDC-4182 | BD-4182; BDC-4182 | Phase 2 Clinical | Bolt Biotherapeutics Inc | Adenocarcinoma; Esophageal Neoplasms; Neoplasms; Stomach Neoplasms | Details |
| AZD-4360 | AZD4360; AZD-4360 | Phase 2 Clinical | Astrazeneca Ab | Biliary Tract Neoplasms; Carcinoma, Pancreatic Ductal; Gastroesophageal Junction Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Claudin18.2 targeting CAR-T cell therapy (Essen Biotech) | Phase 2 Clinical | Essen Biotech | Pancreatic Neoplasms | Details | |
| EB-DNK102 | EB-DNK102 | Phase 2 Clinical | Beijing Biotech | Carcinoma, Pancreatic Ductal | Details |
| HBM-7022 | HBM-7022; AZD-5863 | Phase 2 Clinical | Harbour Biomed | Carcinoma, Pancreatic Ductal; Esophageal adenocarcinoma; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Neoplasms; Pancreatic Neoplasms; Stomach Neoplasms | Details |
| CLDN18.2-TAC T cells Therapy | CLDN-18.2-TAC T cells; CLDN18.2-TAC T cells | Phase 2 Clinical | Triumvira Immunologics Inc | Solid tumours; Stomach Neoplasms | Details |
| KD-182 | KD-182 | Phase 2 Clinical | Nanjing Kaidi Medical Technology Co Ltd | Carcinoma, Pancreatic Ductal; Stomach Neoplasms | Details |
| ASKB-589 | ASKB-589 | Phase 3 Clinical | AskGene Pharma Inc, Jiangsu Aosaikang Pharmaceutical Co Ltd | Adenocarcinoma; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Sonesitatug Vedotin | CMG-901; CMG901; AZD-0901; AZD0901 | Phase 3 Clinical | Keymed Biosciences Co Ltd | Biliary Tract Neoplasms; Carcinoma, Pancreatic Ductal; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| FG-M-108 | FG-M-108; M108; M-108 | Phase 3 Clinical | FutureGen Biopharm (Beijing) Co Ltd | Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Garetatug Rezetecan | SHR-A-1904; SHR-A1904 | Phase 3 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd | Bile Duct Neoplasms; Biliary Tract Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Lymphangioma, Cystic; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| SYSA-1801 | SYSA1801; CPO-102; EO-3021; SYSA-1801 | Phase 3 Clinical | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd | Digestive System Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Gastrointestinal Neoplasms; Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| QLS-31905 | QLS-31905 | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Bile Duct Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Tecotabart vedotin | TPX-4589; BMS-986476; LM-302 | Phase 3 Clinical | LaNova Medicines Ltd | Adenocarcinoma; Digestive System Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Gastrointestinal Neoplasms; Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| JS-107 | JS-107; JS107 | Phase 3 Clinical | Shanghai Junshi Biosciences Co Ltd | Adenocarcinoma; Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| LB-4330 | LB-4330; Bis-2 | Phase 3 Clinical | L&L Biopharma Co Ltd | Solid tumours; Uterine Cervical Neoplasms | Details |
| Arcotatug tavatecan | IBI-343; IBI343 | Phase 3 Clinical | Innovent Biologics(Suzhou) Co Ltd | Adenocarcinoma; Carcinoma, Pancreatic Ductal; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| IMC-002 (Suzhou Immunofoco) | IMC-002 | Phase 3 Clinical | Suzhou Immunofoco Biotechnology Co Ltd | Digestive System Neoplasms; Gastroesophageal Junction Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Stomach Neoplasms | Details |
| XNW-27011 | XNW-27011 | Phase 3 Clinical | Evopoint Biosciences Co Ltd | Adenocarcinoma; Biliary Tract Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Gastroesophageal Junction Neoplasms; Ovarian Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Osemitamab | MSB-018; TST-001 | Phase 3 Clinical | HJB (Hangzhou) Co Ltd, Suzhou Transcenta Therapeutics Co Ltd | Biliary Tract Neoplasms; Esophageal Neoplasms; Gallbladder Neoplasms; Gastroesophageal Junction Neoplasms; Lung Neoplasms; Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
References
Jumper J, et al. Highly accurate protein structure prediction with AlphaFold. Nature (2021)
Furuse M, et al. Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin[J]. J Cell Biol（1998）
- Introduction
- Product list
- Product feature
- Clinical drug information
- References
Share to:
Online Message
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland